<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642941</url>
  </required_header>
  <id_info>
    <org_study_id>NO21157</org_study_id>
    <secondary_id>SARC011</secondary_id>
    <secondary_id>2007-003940-30</secondary_id>
    <nct_id>NCT00642941</nct_id>
    <nct_alias>NCT00615680</nct_alias>
  </id_info>
  <brief_title>A Study of R1507 in Participants With Recurrent or Refractory Sarcoma</brief_title>
  <official_title>A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Participants With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sarcoma Alliance for Research through Collaboration</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      The study was primarily designed to determine objective response, progression-free survival&#xD;
      (PFS), and the safety and tolerability of R1507 in participants with recurrent or refractory&#xD;
      Ewing's sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma and other sarcomas&#xD;
      including alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal&#xD;
      myxoid chondrosarcoma, clear cell sarcoma, and myxoid liposarcoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was closed to further enrollment due to the decision by the Sponsor to discontinue&#xD;
    development of R1507.&#xD;
  </why_stopped>
  <start_date type="Actual">December 18, 2007</start_date>
  <completion_date type="Actual">February 19, 2014</completion_date>
  <primary_completion_date type="Actual">February 19, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Complete or Partial Response, According to World Health Organization (WHO) Criteria in Cohorts 2 to 8</measure>
    <time_frame>Baseline up to 6 years (assessed at baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression)</time_frame>
    <description>Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is &gt;=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS) Rate According to WHO Response Criteria at 18 Weeks From Start of R2607 Treatment in Cohort 1</measure>
    <time_frame>Baseline up to 18 weeks (assessed at baseline, every 6 weeks until disease progression)</time_frame>
    <description>The PFS survival rate is a landmark analysis of progression-free survival at 18 weeks from start of treatment. Progression-free survival rate at 18 weeks is a dichotomous endpoint, with a patient categorized as alive (with either stable disease or objective response) at 18 weeks from start of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Events (AEs) in Cohort 1 and 2</measure>
    <time_frame>Baseline up to 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Complete or Partial Response According to WHO Response Criteria in Cohort 1</measure>
    <time_frame>Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)</time_frame>
    <description>Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is &gt;=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS Rate According to WHO Response Criteria at 18 Weeks From Start of R1507 Treatment in Cohorts 2 to 8</measure>
    <time_frame>Baseline, every 6 weeks until disease progression (up to 18 weeks)</time_frame>
    <description>The PFS survival rate is a landmark analysis of progression-free survival at 18 weeks from start of treatment. Progression-free survival rate at 18 weeks is a dichotomous endpoint, with a patient categorized as alive (with either stable disease or objective response at 18 weeks) from start of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With AEs in Cohorts 3-8</measure>
    <time_frame>Baseline up to 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) According to WHO Response Criteria in Cohorts 1 to 8</measure>
    <time_frame>Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)</time_frame>
    <description>The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is &gt;=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP) According to WHO Response Criteria in Cohorts 1 to 8</measure>
    <time_frame>Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)</time_frame>
    <description>TTP is defined as the time from date of randomization until objective tumor progression. According to the WHO Response Criteria, objective tumor progression is &gt; 25% increase in the area of one or more measurable lesions or the appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure-Free Survival (FFS) According to WHO Response Criteria in Cohorts 1 to 8</measure>
    <time_frame>Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)</time_frame>
    <description>FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) in Cohorts 1 to 8</measure>
    <time_frame>Baseline until death (up to 6 years)</time_frame>
    <description>OS was measured from the time of study registration to the date of death or was censored at the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS According to WHO Response Criteria in Cohorts 1 to 8</measure>
    <time_frame>Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)</time_frame>
    <description>PFS is defined as the duration of time from start of treatment to time of objective progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of R1507</measure>
    <time_frame>Predose (0 hours [h]), end of 60-90 minutes infusion (EOI), postdose (2, 24, 72-96 h) in Week 1; predose (0 h) and EOI in Weeks 2, 4, 6, 9; predose (0 h), EOI, postdose (48 h) in Week 12; predose (0 h) in Week 13, at final visit (up to 6 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Clearance (CL) of R1507</measure>
    <time_frame>Predose (0 h), EOI (infusion over 60-90 minutes), postdose (2, 24, 72-96 h) in Week 1; predose (0 h) and EOI in Weeks 2, 4, 6, 9; predose (0 h), EOI, postdose (48 h) in Week 12; predose (0 h) in Week 13, at final visit (up to 6 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">317</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Ewings Sarcoma Primary Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Ewings Sarcoma Secondary Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: Ewings Sarcoma Expanded Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4: Osteosarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5: Synovial Sarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6: Rhabdomyosarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7a: Alveolar Soft Part Sarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a includes individuals with alveolar soft part sarcoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7b: Desmoplastic Small Round Cell Tumors.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7d: Clear Cell Sarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7e: Myxoid Liposarcoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 8: Diagnosis Not Specified</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RG1507</intervention_name>
    <description>Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.</description>
    <arm_group_label>Cohort 1: Ewings Sarcoma Primary Cohort</arm_group_label>
    <arm_group_label>Cohort 2: Ewings Sarcoma Secondary Cohort</arm_group_label>
    <arm_group_label>Cohort 3: Ewings Sarcoma Expanded Cohort</arm_group_label>
    <arm_group_label>Cohort 4: Osteosarcoma</arm_group_label>
    <arm_group_label>Cohort 5: Synovial Sarcoma</arm_group_label>
    <arm_group_label>Cohort 6: Rhabdomyosarcoma</arm_group_label>
    <arm_group_label>Cohort 7a: Alveolar Soft Part Sarcoma</arm_group_label>
    <arm_group_label>Cohort 7b: Desmoplastic Small Round Cell Tumors.</arm_group_label>
    <arm_group_label>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</arm_group_label>
    <arm_group_label>Cohort 7d: Clear Cell Sarcoma</arm_group_label>
    <arm_group_label>Cohort 7e: Myxoid Liposarcoma</arm_group_label>
    <arm_group_label>Cohort 8: Diagnosis Not Specified</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  progressive, recurrent or refractory Ewing's sarcoma, or recurrent or refractory&#xD;
             osteosarcoma, synovial sarcoma, rhabdomyosarcoma, or other sarcomas of the following&#xD;
             sub-types: alveolar soft part sarcoma, desmoplastic small round cell tumor,&#xD;
             extraskeletal myxoid chondrosarcoma, clear cell sarcoma and myxoid liposarcoma;&#xD;
&#xD;
          -  Cohort 3 only: age must be &gt;= 2 and &lt;= 21 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  clinically significant unrelated systemic illness which would compromise the&#xD;
             participant's ability to tolerate the investigational agent, or interfere with the&#xD;
             study procedures or results;&#xD;
&#xD;
          -  known hypersensitivity to any of the components of R1507 or prior hypersensitivity&#xD;
             reactions to monoclonal antibodies;&#xD;
&#xD;
          -  treatment (within the past 2 weeks) with pharmacologic doses of corticosteroids or&#xD;
             other immunosuppressive agents;&#xD;
&#xD;
          -  current or prior therapy with insulin-like growth factor (IGF) inhibitor (monoclonal&#xD;
             or specific kinase inhibitor);&#xD;
&#xD;
          -  history of solid organ transplant;&#xD;
&#xD;
          -  other malignant disease diagnosed within the previous 5 years, excluding&#xD;
             intra-epithelial cervical neoplasia or non-melanoma skin cancer;&#xD;
&#xD;
          -  active central nervous system disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA School Of Medicine Mattel's Children's Hospital At UCLA; Division Of Hematology-Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Comprehensive Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Cancer Institute; Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kootenai Medical Center</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIH/NCI</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital; Dana Farber Partnes Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Partners Can Ctr</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115-6084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital; Onc Hem West</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein College of Medical Pediatrics; Department of Pediatrics</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Hematology Oncology Associates; Investigational Drug Services - Pharmacy</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennsylvania Oncology Hema Asc</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Cancer Center; Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute; Orthopedic Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Maccallum Cancer Institute; Medical Oncology</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA-Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie; Oncologie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret; Chir Cancerologie General</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard; Departement Oncologie Medicale</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie; Oncologie Medicale</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy; Service Pediatrique</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Bad Saarow; Klinik für Innere Medizin III</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Mannheim; Sektion Chirurgische Onkologie &amp; Thoraxchirurgie</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituti Ortopedici Rizzoli</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori, Sarcoma Unit</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Mc - Daniel Den Hoed Kliniek; Medical Oncology</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan De Deu</name>
      <address>
        <city>Esplugues De Llobregas</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skånes University Hospital, Skånes Department of Onclology</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCL Hospital NHS Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital; Dept of Med-Onc</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital NHS Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Finland</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 19, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2008</study_first_posted>
  <results_first_submitted>September 9, 2020</results_first_submitted>
  <results_first_submitted_qc>January 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 3, 2021</results_first_posted>
  <disposition_first_submitted>November 2, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>November 2, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 3, 2016</disposition_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A screening period was included prior to administration of study drug. Tumor scans/X-rays were to be obtained within 4 weeks, fluro-D-glucose positron emission tomography (FDG-PET) scans within 2 weeks, and Baseline laboratory evaluations within 1 week before first dose.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1: Ewings Sarcoma Primary Cohort</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 2: Ewings Sarcoma Secondary Cohort</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 3: Ewings Sarcoma Expanded Cohort</title>
          <description>Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 4: Osteosarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.</description>
        </group>
        <group group_id="P5">
          <title>Cohort 5: Synovial Sarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.</description>
        </group>
        <group group_id="P6">
          <title>Cohort 6: Rhabdomyosarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.</description>
        </group>
        <group group_id="P7">
          <title>Cohort 7a: Alveolar Soft Part Sarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma received R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a included individuals with alveolar soft part sarcoma.</description>
        </group>
        <group group_id="P8">
          <title>Cohort 7b: Desmoplastic Small Round Cell Tumors.</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.</description>
        </group>
        <group group_id="P9">
          <title>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.</description>
        </group>
        <group group_id="P10">
          <title>Cohort 7d: Clear Cell Sarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.</description>
        </group>
        <group group_id="P11">
          <title>Cohort 7e: Myxoid Liposarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.</description>
        </group>
        <group group_id="P12">
          <title>Cohort 8: Diagnosis Not Specified</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="41"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="11"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="41"/>
                <participants group_id="P7" count="23"/>
                <participants group_id="P8" count="14"/>
                <participants group_id="P9" count="11"/>
                <participants group_id="P10" count="9"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study closed by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="23"/>
                <participants group_id="P6" count="39"/>
                <participants group_id="P7" count="18"/>
                <participants group_id="P8" count="12"/>
                <participants group_id="P9" count="10"/>
                <participants group_id="P10" count="7"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1: Ewings Sarcoma Primary Cohort</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 2: Ewings Sarcoma Secondary Cohort</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 3: Ewings Sarcoma Expanded Cohort</title>
          <description>Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 4: Osteosarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.</description>
        </group>
        <group group_id="B5">
          <title>Cohort 5: Synovial Sarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.</description>
        </group>
        <group group_id="B6">
          <title>Cohort 6: Rhabdomyosarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.</description>
        </group>
        <group group_id="B7">
          <title>Cohort 7a: Alveolar Soft Part Sarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma received R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a included individuals with alveolar soft part sarcoma.</description>
        </group>
        <group group_id="B8">
          <title>Cohort 7b: Desmoplastic Small Round Cell Tumors.</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.</description>
        </group>
        <group group_id="B9">
          <title>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.</description>
        </group>
        <group group_id="B10">
          <title>Cohort 7d: Clear Cell Sarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.</description>
        </group>
        <group group_id="B11">
          <title>Cohort 7e: Myxoid Liposarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.</description>
        </group>
        <group group_id="B12">
          <title>Cohort 8: Diagnosis Not Specified</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="25"/>
            <count group_id="B6" value="41"/>
            <count group_id="B7" value="23"/>
            <count group_id="B8" value="14"/>
            <count group_id="B9" value="11"/>
            <count group_id="B10" value="9"/>
            <count group_id="B11" value="12"/>
            <count group_id="B12" value="11"/>
            <count group_id="B13" value="317"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27" spread="10.72"/>
                    <measurement group_id="B2" value="28.3" spread="12.9"/>
                    <measurement group_id="B3" value="13.3" spread="3.15"/>
                    <measurement group_id="B4" value="33.8" spread="18.83"/>
                    <measurement group_id="B5" value="41.7" spread="16.11"/>
                    <measurement group_id="B6" value="26.5" spread="12.21"/>
                    <measurement group_id="B7" value="31.7" spread="13.67"/>
                    <measurement group_id="B8" value="23.1" spread="6.09"/>
                    <measurement group_id="B9" value="60.9" spread="11.27"/>
                    <measurement group_id="B10" value="26.9" spread="11.01"/>
                    <measurement group_id="B11" value="50.6" spread="11.06"/>
                    <measurement group_id="B12" value="30.7" spread="18.56"/>
                    <measurement group_id="B13" value="31.2" spread="13.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="3"/>
                    <measurement group_id="B13" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="11"/>
                    <measurement group_id="B8" value="13"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="9"/>
                    <measurement group_id="B12" value="8"/>
                    <measurement group_id="B13" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete or Partial Response, According to World Health Organization (WHO) Criteria in Cohorts 2 to 8</title>
        <description>Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is &gt;=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.</description>
        <time_frame>Baseline up to 6 years (assessed at baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression)</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment. There were 0 participants analyzed for Cohort 3 due to no efficacy data being collected for that cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Ewings Sarcoma Secondary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3: Ewings Sarcoma Expanded Cohort</title>
            <description>Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4: Osteosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 5: Synovial Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 6: Rhabdomyosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 7a: Alveolar Soft Part Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma received R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a included individuals with alveolar soft part sarcoma.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7b: Desmoplastic Small Round Cell Tumors.</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7d: Clear Cell Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7e: Myxoid Liposarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 8: Diagnosis Not Specified</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete or Partial Response, According to World Health Organization (WHO) Criteria in Cohorts 2 to 8</title>
          <description>Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is &gt;=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment. There were 0 participants analyzed for Cohort 3 due to no efficacy data being collected for that cohort.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="14"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.11"/>
                    <measurement group_id="O3" value="2.5"/>
                    <measurement group_id="O4" value="4.0"/>
                    <measurement group_id="O5" value="4.88"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-Free Survival (PFS) Rate According to WHO Response Criteria at 18 Weeks From Start of R2607 Treatment in Cohort 1</title>
        <description>The PFS survival rate is a landmark analysis of progression-free survival at 18 weeks from start of treatment. Progression-free survival rate at 18 weeks is a dichotomous endpoint, with a patient categorized as alive (with either stable disease or objective response) at 18 weeks from start of treatment.</description>
        <time_frame>Baseline up to 18 weeks (assessed at baseline, every 6 weeks until disease progression)</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ewings Sarcoma Primary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-Free Survival (PFS) Rate According to WHO Response Criteria at 18 Weeks From Start of R2607 Treatment in Cohort 1</title>
          <description>The PFS survival rate is a landmark analysis of progression-free survival at 18 weeks from start of treatment. Progression-free survival rate at 18 weeks is a dichotomous endpoint, with a patient categorized as alive (with either stable disease or objective response) at 18 weeks from start of treatment.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Events (AEs) in Cohort 1 and 2</title>
        <time_frame>Baseline up to 6 years</time_frame>
        <population>Safety Population: All participants who received at least one dose of study drug at had at least one safety follow-up assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ewings Sarcoma Primary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ewings Sarcoma Secondary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events (AEs) in Cohort 1 and 2</title>
          <population>Safety Population: All participants who received at least one dose of study drug at had at least one safety follow-up assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Complete or Partial Response According to WHO Response Criteria in Cohort 1</title>
        <description>Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is &gt;=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.</description>
        <time_frame>Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ewings Sarcoma Primary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete or Partial Response According to WHO Response Criteria in Cohort 1</title>
          <description>Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is &gt;=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS Rate According to WHO Response Criteria at 18 Weeks From Start of R1507 Treatment in Cohorts 2 to 8</title>
        <description>The PFS survival rate is a landmark analysis of progression-free survival at 18 weeks from start of treatment. Progression-free survival rate at 18 weeks is a dichotomous endpoint, with a patient categorized as alive (with either stable disease or objective response at 18 weeks) from start of treatment.</description>
        <time_frame>Baseline, every 6 weeks until disease progression (up to 18 weeks)</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment. There were 0 participants analyzed for Cohort 3 due to no efficacy data being collected for that cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 2: Ewings Sarcoma Secondary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 3: Ewings Sarcoma Expanded Cohort</title>
            <description>Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 4: Osteosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 5: Synovial Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 6: Rhabdomyosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 7a: Alveolar Soft Part Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma received R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a included individuals with alveolar soft part sarcoma.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7b: Desmoplastic Small Round Cell Tumors.</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7e: Myxoid Liposarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Clear Cell Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 8: Diagnosis Not Specified</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS Rate According to WHO Response Criteria at 18 Weeks From Start of R1507 Treatment in Cohorts 2 to 8</title>
          <description>The PFS survival rate is a landmark analysis of progression-free survival at 18 weeks from start of treatment. Progression-free survival rate at 18 weeks is a dichotomous endpoint, with a patient categorized as alive (with either stable disease or objective response at 18 weeks) from start of treatment.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment. There were 0 participants analyzed for Cohort 3 due to no efficacy data being collected for that cohort.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="23"/>
                <count group_id="O7" value="14"/>
                <count group_id="O8" value="11"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="12"/>
                <count group_id="O11" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.16"/>
                    <measurement group_id="O3" value="19.69"/>
                    <measurement group_id="O4" value="4.00"/>
                    <measurement group_id="O5" value="7.32"/>
                    <measurement group_id="O6" value="45.40"/>
                    <measurement group_id="O7" value="8.16"/>
                    <measurement group_id="O8" value="62.34"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="8.33"/>
                    <measurement group_id="O11" value="22.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With AEs in Cohorts 3-8</title>
        <time_frame>Baseline up to 6 years</time_frame>
        <population>Safety Population: All participants who received at least one dose of study drug at had at least one safety follow-up assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 3: Ewings Sarcoma Expanded Cohort</title>
            <description>Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 4: Osteosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 5: Synovial Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 6: Rhabdomyosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 7a: Alveolar Soft Part Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma received R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a included individuals with alveolar soft part sarcoma.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 7b: Desmoplastic Small Round Cell Tumors.</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7d: Clear Cell Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7e: Myxoid Liposarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 8: Diagnosis Not Specified</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With AEs in Cohorts 3-8</title>
          <population>Safety Population: All participants who received at least one dose of study drug at had at least one safety follow-up assessment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="41"/>
                <count group_id="O5" value="23"/>
                <count group_id="O6" value="14"/>
                <count group_id="O7" value="11"/>
                <count group_id="O8" value="9"/>
                <count group_id="O9" value="12"/>
                <count group_id="O10" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.7"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="91"/>
                    <measurement group_id="O6" value="86"/>
                    <measurement group_id="O7" value="100"/>
                    <measurement group_id="O8" value="100"/>
                    <measurement group_id="O9" value="100"/>
                    <measurement group_id="O10" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR) According to WHO Response Criteria in Cohorts 1 to 8</title>
        <description>The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is &gt;=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.</description>
        <time_frame>Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment. There were 0 participants analyzed for Cohort 3, 7 and 8 due to no DOR data being collected for these cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ewings Sarcoma Primary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ewings Sarcoma Secondary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Ewings Sarcoma Expanded Cohort</title>
            <description>Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Osteosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: Synovial Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Rhabdomyosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: Alveolar Soft Part Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma received R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a included individuals with alveolar soft part sarcoma.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Desmoplastic Small Round Cell Tumors.</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Clear Cell Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7e: Myxoid Liposarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.</description>
          </group>
          <group group_id="O12">
            <title>Cohort 8: Diagnosis Not Specified</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR) According to WHO Response Criteria in Cohorts 1 to 8</title>
          <description>The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is &gt;=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment. There were 0 participants analyzed for Cohort 3, 7 and 8 due to no DOR data being collected for these cohorts.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="41"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.29" lower_limit="18" upper_limit="NA">Upper limit was not reached due to low number of events.</measurement>
                    <measurement group_id="O2" value="42.86" lower_limit="18.14" upper_limit="NA">Upper limit was not reached due to low number of events.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="30.14" upper_limit="NA">DOR and upper limit were not reached due to low number of events.</measurement>
                    <measurement group_id="O5" value="13.14" lower_limit="13.14" upper_limit="NA">Upper limit was not reached due to low number of events.</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="21" upper_limit="NA">DOR and upper limit were not reached due to low number of events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP) According to WHO Response Criteria in Cohorts 1 to 8</title>
        <description>TTP is defined as the time from date of randomization until objective tumor progression. According to the WHO Response Criteria, objective tumor progression is &gt; 25% increase in the area of one or more measurable lesions or the appearance of new lesions.</description>
        <time_frame>Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment. There were 0 participants analyzed for Cohort 3 due to no efficacy data being collected for that cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ewings Sarcoma Primary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ewings Sarcoma Secondary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Ewings Sarcoma Expanded Cohort</title>
            <description>Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Osteosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: Synovial Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Rhabdomyosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: Alveolar Soft Part Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma received R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a included individuals with alveolar soft part sarcoma.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Desmoplastic Small Round Cell Tumors.</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Clear Cell Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7e: Myxoid Liposarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.</description>
          </group>
          <group group_id="O12">
            <title>Cohort 8: Diagnosis Not Specified</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP) According to WHO Response Criteria in Cohorts 1 to 8</title>
          <description>TTP is defined as the time from date of randomization until objective tumor progression. According to the WHO Response Criteria, objective tumor progression is &gt; 25% increase in the area of one or more measurable lesions or the appearance of new lesions.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment. There were 0 participants analyzed for Cohort 3 due to no efficacy data being collected for that cohort.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="41"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="14"/>
                <count group_id="O9" value="11"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="5.29" upper_limit="9.71"/>
                    <measurement group_id="O2" value="6.00" lower_limit="5.71" upper_limit="8.14"/>
                    <measurement group_id="O4" value="5.71" lower_limit="5.57" upper_limit="7.00"/>
                    <measurement group_id="O5" value="6.00" lower_limit="5.57" upper_limit="6.43"/>
                    <measurement group_id="O6" value="5.50" lower_limit="5.14" upper_limit="6.14"/>
                    <measurement group_id="O7" value="11.14" lower_limit="6.00" upper_limit="17.71"/>
                    <measurement group_id="O8" value="6.14" lower_limit="5.86" upper_limit="11.14"/>
                    <measurement group_id="O9" value="18.00" lower_limit="5.71" upper_limit="NA">Upper limit was not reached due to low number of events.</measurement>
                    <measurement group_id="O10" value="5.57" lower_limit="5.14" upper_limit="5.86"/>
                    <measurement group_id="O11" value="5.86" lower_limit="5.29" upper_limit="8.43"/>
                    <measurement group_id="O12" value="6.14" lower_limit="5.86" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Failure-Free Survival (FFS) According to WHO Response Criteria in Cohorts 1 to 8</title>
        <description>FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause.</description>
        <time_frame>Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)</time_frame>
        <population>Data was not collected for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ewings Sarcoma Primary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ewings Sarcoma Secondary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Ewings Sarcoma Expanded Cohort</title>
            <description>Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Osteosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: Synovial Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Rhabdomyosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: Alveolar Soft Part Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma received R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a included individuals with alveolar soft part sarcoma.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Desmoplastic Small Round Cell Tumors.</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Clear Cell Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7e: Myxoid Liposarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.</description>
          </group>
          <group group_id="O12">
            <title>Cohort 8: Diagnosis Not Specified</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Failure-Free Survival (FFS) According to WHO Response Criteria in Cohorts 1 to 8</title>
          <description>FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause.</description>
          <population>Data was not collected for this endpoint.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) in Cohorts 1 to 8</title>
        <description>OS was measured from the time of study registration to the date of death or was censored at the date of last contact.</description>
        <time_frame>Baseline until death (up to 6 years)</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment. There were 0 participants analyzed for Cohort 3 and 7c due to no overall survival data being collected for those cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ewings Sarcoma Primary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ewings Sarcoma Secondary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Ewings Sarcoma Expanded Cohort</title>
            <description>Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Osteosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: Synovial Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Rhabdomyosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: Alveolar Soft Part Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma received R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a included individuals with alveolar soft part sarcoma.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Desmoplastic Small Round Cell Tumors.</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Clear Cell Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7e: Myxoid Liposarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.</description>
          </group>
          <group group_id="O12">
            <title>Cohort 8: Diagnosis Not Specified</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) in Cohorts 1 to 8</title>
          <description>OS was measured from the time of study registration to the date of death or was censored at the date of last contact.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment. There were 0 participants analyzed for Cohort 3 and 7c due to no overall survival data being collected for those cohorts.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="61"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="14"/>
                <count group_id="O9" value="11"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.57" lower_limit="20.57" upper_limit="37.57"/>
                    <measurement group_id="O2" value="43.57" lower_limit="33.29" upper_limit="69.00"/>
                    <measurement group_id="O4" value="37.14" lower_limit="25.57" upper_limit="NA">Upper limit was not reached due to low number of events.</measurement>
                    <measurement group_id="O5" value="40.71" lower_limit="21.71" upper_limit="64.14"/>
                    <measurement group_id="O6" value="30.86" lower_limit="21.57" upper_limit="50.00"/>
                    <measurement group_id="O7" value="42.43" lower_limit="42.43" upper_limit="NA">Upper limit was not reached due to low number of events.</measurement>
                    <measurement group_id="O8" value="40.86" lower_limit="23.57" upper_limit="NA">Upper limit was not reached due to low number of events.</measurement>
                    <measurement group_id="O9" value="NA" lower_limit="NA" upper_limit="NA">All participants were censored as no deaths occurred.</measurement>
                    <measurement group_id="O10" value="17.00" lower_limit="9.14" upper_limit="NA">Upper limit was not reached due to low number of events.</measurement>
                    <measurement group_id="O11" value="36.00" lower_limit="33.14" upper_limit="NA">Upper limit was not reached due to low number of events.</measurement>
                    <measurement group_id="O12" value="17.43" lower_limit="13.00" upper_limit="30.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS According to WHO Response Criteria in Cohorts 1 to 8</title>
        <description>PFS is defined as the duration of time from start of treatment to time of objective progression or death.</description>
        <time_frame>Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)</time_frame>
        <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment. There were 0 participants analyzed for Cohort 3 due to no efficacy data being collected for that cohort.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ewings Sarcoma Primary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ewings Sarcoma Secondary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Ewings Sarcoma Expanded Cohort</title>
            <description>Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Osteosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: Synovial Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Rhabdomyosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: Alveolar Soft Part Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma received R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a included individuals with alveolar soft part sarcoma.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Desmoplastic Small Round Cell Tumors.</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Clear Cell Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7e: Myxoid Liposarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.</description>
          </group>
          <group group_id="O12">
            <title>Cohort 8: Diagnosis Not Specified</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS According to WHO Response Criteria in Cohorts 1 to 8</title>
          <description>PFS is defined as the duration of time from start of treatment to time of objective progression or death.</description>
          <population>ITT population included all randomized participants who received at least 1 dose of study drug and had at least 1 post baseline efficacy assessment. There were 0 participants analyzed for Cohort 3 due to no efficacy data being collected for that cohort.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="41"/>
                <count group_id="O7" value="23"/>
                <count group_id="O8" value="14"/>
                <count group_id="O9" value="11"/>
                <count group_id="O10" value="9"/>
                <count group_id="O11" value="12"/>
                <count group_id="O12" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="5.29" upper_limit="9.57"/>
                    <measurement group_id="O2" value="6.00" lower_limit="5.71" upper_limit="8.14"/>
                    <measurement group_id="O4" value="5.71" lower_limit="5.57" upper_limit="6.43"/>
                    <measurement group_id="O5" value="6.00" lower_limit="5.43" upper_limit="6.14"/>
                    <measurement group_id="O6" value="5.43" lower_limit="5.14" upper_limit="6.14"/>
                    <measurement group_id="O7" value="11.14" lower_limit="5.71" upper_limit="11.71"/>
                    <measurement group_id="O8" value="6.14" lower_limit="5.86" upper_limit="11.14"/>
                    <measurement group_id="O9" value="18.00" lower_limit="5.71" upper_limit="NA">Upper limit was not reached due to low number of events.</measurement>
                    <measurement group_id="O10" value="5.57" lower_limit="5.14" upper_limit="5.86"/>
                    <measurement group_id="O11" value="5.86" lower_limit="5.29" upper_limit="8.43"/>
                    <measurement group_id="O12" value="6.14" lower_limit="5.86" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of R1507</title>
        <time_frame>Predose (0 hours [h]), end of 60-90 minutes infusion (EOI), postdose (2, 24, 72-96 h) in Week 1; predose (0 h) and EOI in Weeks 2, 4, 6, 9; predose (0 h), EOI, postdose (48 h) in Week 12; predose (0 h) in Week 13, at final visit (up to 6 years)</time_frame>
        <population>Data was not collected for this pharmacokinetic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ewings Sarcoma Primary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ewings Sarcoma Secondary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Ewings Sarcoma Expanded Cohort</title>
            <description>Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Osteosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: Synovial Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Rhabdomyosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: Alveolar Soft Part Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma received R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a included individuals with alveolar soft part sarcoma.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Desmoplastic Small Round Cell Tumors.</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Clear Cell Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7e: Myxoid Liposarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.</description>
          </group>
          <group group_id="O12">
            <title>Cohort 8: Diagnosis Not Specified</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of R1507</title>
          <population>Data was not collected for this pharmacokinetic endpoint.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Clearance (CL) of R1507</title>
        <time_frame>Predose (0 h), EOI (infusion over 60-90 minutes), postdose (2, 24, 72-96 h) in Week 1; predose (0 h) and EOI in Weeks 2, 4, 6, 9; predose (0 h), EOI, postdose (48 h) in Week 12; predose (0 h) in Week 13, at final visit (up to 6 years)</time_frame>
        <population>Data was not collected for this pharmacokinetic endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1: Ewings Sarcoma Primary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 2: Ewings Sarcoma Secondary Cohort</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 3: Ewings Sarcoma Expanded Cohort</title>
            <description>Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 4: Osteosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.</description>
          </group>
          <group group_id="O5">
            <title>Cohort 5: Synovial Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.</description>
          </group>
          <group group_id="O6">
            <title>Cohort 6: Rhabdomyosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.</description>
          </group>
          <group group_id="O7">
            <title>Cohort 7a: Alveolar Soft Part Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma received R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a included individuals with alveolar soft part sarcoma.</description>
          </group>
          <group group_id="O8">
            <title>Cohort 7b: Desmoplastic Small Round Cell Tumors.</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.</description>
          </group>
          <group group_id="O9">
            <title>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.</description>
          </group>
          <group group_id="O10">
            <title>Cohort 7d: Clear Cell Sarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.</description>
          </group>
          <group group_id="O11">
            <title>Cohort 7e: Myxoid Liposarcoma</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.</description>
          </group>
          <group group_id="O12">
            <title>Cohort 8: Diagnosis Not Specified</title>
            <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Clearance (CL) of R1507</title>
          <population>Data was not collected for this pharmacokinetic endpoint.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 6 years</time_frame>
      <desc>Safety Population: All participants who received at least one dose of study drug at had at least one safety follow-up assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1: Ewings Sarcoma Primary Cohort</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 2: Ewings Sarcoma Secondary Cohort</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 3: Ewings Sarcoma Expanded Cohort</title>
          <description>Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 4: Osteosarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.</description>
        </group>
        <group group_id="E5">
          <title>Cohort 5: Synovial Sarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.</description>
        </group>
        <group group_id="E6">
          <title>Cohort 6: Rhabdomyosarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.</description>
        </group>
        <group group_id="E7">
          <title>Cohort 7a: Alveolar Soft Part Sarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma received R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a included individuals with alveolar soft part sarcoma.</description>
        </group>
        <group group_id="E8">
          <title>Cohort 7b: Desmoplastic Small Round Cell Tumors</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.</description>
        </group>
        <group group_id="E9">
          <title>Cohort 7c: Extraskeletal Myxoid Chondrosarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.</description>
        </group>
        <group group_id="E10">
          <title>Cohort 7d: Clear Cell Sarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.</description>
        </group>
        <group group_id="E11">
          <title>Cohort 7e: Myxoid Liposarcoma</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.</description>
        </group>
        <group group_id="E12">
          <title>Cohort 8: Diagnosis Not Specified</title>
          <description>Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Facial palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.05</frequency_threshold>
        <default_vocab>MedDRA v13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haemoglobinaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pericardia effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Borrelia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Platelet count</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood creatinine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Carbon dioxide decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neutrophil count</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>White blood cell count</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haematocrit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urine bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypermagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Decreased activity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Testicular torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was closed to further enrollment due to a decision by the Sponsor to discontinue development of R1507. The decision was made based upon available data from other completed/ongoing trials of R1507 and was not due to safety concerns.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>F. Hoffmann-La Roche AG</organization>
      <phone>+41 616878333</phone>
      <email>global.trial_information@roche.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

